enGene Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
enGene Therapeutics Inc. (ENGN) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$210.00 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-09-08
- enGene Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-07-31 was -$210.00K.
- enGene Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-04-30 was -$299.00K, a 197.71% decline year-over-year.
- enGene Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-01-31 was $46.00K, a 68.06% decline year-over-year.
- enGene Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-07-31 was -$240.00K.
- enGene Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $531.00K.
- enGene Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$403.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$210.00K 10-Q · filed 2026-09-08 | -$509.00K derived: sum of 2 quarters · filed 2026-09-08 | -$463.00K derived: sum of 3 quarters · filed 2026-09-08 | |
| 2026-04-30 | -$299.00K 10-Q · filed 2026-09-08 | -$253.00K derived: sum of 2 quarters · filed 2026-09-08 | ||
| 2026-01-31 | $46.00K 10-Q · filed 2026-09-08 | |||
| 2025-10-31 | $531.00K 10-K · filed 2025-12-22 | |||
| 2025-07-31 | -$240.00K 10-Q · filed 2026-09-08 | $66.00K derived: sum of 2 quarters · filed 2026-09-08 | $210.00K derived: sum of 3 quarters · filed 2026-09-08 | |
| 2025-04-30 | $306.00K 10-Q · filed 2026-09-08 | $450.00K derived: sum of 2 quarters · filed 2026-09-08 | ||
| 2025-01-31 | $144.00K 10-Q · filed 2026-09-08 | |||
| 2024-10-31 | -$403.00K 10-K · filed 2025-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |